Across TCGA pan-cancer cohorts, TRAV26-2 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated TRAV26-2 data layer compared with 2 for mutation status.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TRAV26-2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated TRAV26-2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and HNSC show a favorable association.
SKCM, HNSC, and ESCA are the cancer types where TRAV26-2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.